Hansa Medical announces prospectus
The information in this press release is not directed at persons located in Australia, Canada, Hong Kong, Japan, New Zealand, the Republic of Korea, Singapore, South Africa, Switzerland, the United States or any other country where the offer or sale of subscription rights, interim shares or new shares is not permitted. The information may not be published or distributed, directly or indirectly, in or into, any of the aforementioned countries or any other country where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, other offer documentation, registrations or other actions in addition to what follows from Swedish law. Nor may the information be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions or gives cause to such requirements. Failure to comply with these instructions may result in a violation of the United States Securities Act of 1933, as amended (“Securities Act”) or laws applicable in other jurisdictions.
The information in this press release does not contain or constitute an invitation or an offer to acquire, sell, subscribe for or otherwise trade in shares, subscription rights or other securities in Hansa Medical AB. No subscription rights, interim shares or new shares will be registered under the Securities Act or in accordance with any other rules or regulations in any other country than Sweden and may not be transferred or offered for sale in the United States or any country where such transfer or offer may be prohibited, or to persons resident in any such country or on account of such persons, other than pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act or similar legislation in another country, respectively.
The Board of Hansa Medical AB (publ) has prepared a prospectus for the purpose of the rights issue, which was announced on February 23, 2015. The prospectus has today, March 17, 2015, been approved by and registered with the Swedish Financial Supervisory Authority ( Sw . Finansinspektionen ) in accordance with the Financial Instruments Trading Act ( Sw. lagen (1991:980) om handel med finansiella instrument ).
The prospectus is available on Hansa Medical’s website (www.hansamedical.com) and Carnegie Investment Bank AB’s website (www.carnegie.se) and will be available on the Swedish Financial Supervisory Authority’s website (www.fi.se/Register/Prospektregistret).
The prospectus contains revised financial statements of historical financial information regarding the financial years of 2012 and 2013, which have been audited by the company’s auditor. Furthermore, the prospectus contains reviewed interim financial information as at 31 December 2014 and the twelve-month period which ended on this day, including notes to the financial information. The information in the notes for the three financial years is partly not previously disclosed. As earlier announced, the company’s annual report of 2014 will be published on March 23, 2015.
The proceeds form the rights issue will be used for financing pivotal development activities regarding IdeS, preclinical development of second generation IdeS and evaluate development opportunities for EndoS.
IdeS, a unique molecule with a novel mechanism, is a bacterial enzyme that cleaves human IgG antibodies. IdeS degrades all IgG specifically, swiftly and efficiently. IdeS has been tested for safety and efficacy in numerous in vitro and in vivo models. During 2013, a Phase I clinical trial on 29 healthy subjects was conducted, demonstrating IdeS as efficacious and well tolerated with a favorable safety profile. During 2014 and 2015, a Phase II clinical trial in sensitized patients awaiting kidney transplantation has been conducted. Preliminary data shows that IdeS has very good efficacy in highly sensitized patients on the kidney transplant waitlist. The study shows that IdeS has the capacity to make sensitized patients eligible for transplantation by decreasing HLA antibodies to levels acceptable for transplantation. In addition to transplantation, IdeS has potential indications within a variety of rare autoimmune diseases including anti-GBM disease. IdeS is protected by several patents and has been published in numerous peer review journals.
The information in this press release is disclosed pursuant to the Securities Markets Act or the Financial Instruments Trading Act. The information was released for public disclosure on March 18, 2015 at 10.15 CET.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CFO and acting CEO
Mobile: 46 706-33 30 42
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.